Market Spotlight: Fibromyalgia
Market Spotlight: Fibromyalgia
$1,318.00
This Market Spotlight report covers the Fibromyalgia market, comprising key marketed and pipeline drugs, clinical trials, recent events and analyst opinion, upcoming events, probability of success, patent information, and prevalence data, as well as presenting drug-specific revenue forecasts.
Author: Informa Pharma Intelligence
Publisher: Datamonitor Healthcare
- Description
- Contents
This Market Spotlight report covers the Fibromyalgia market, comprising key marketed and pipeline drugs, clinical trials, recent events and analyst opinion, upcoming events, probability of success, patent information, and prevalence data, as well as presenting drug-specific revenue forecasts.
Key Takeaways
- The approved drugs in the fibromyalgia space target dopamine reuptake, norepinephrine (noradrenaline) reuptake/transporter, serotonin reuptake, and voltage-gated calcium channels. All of the marketed drugs for fibromyalgia are administered via the oral route.
- The majority of industry-sponsored drugs in active clinical development for fibromyalgia are in Phase II, with two drugs in Phase III.
- Therapies in development for fibromyalgia focus on a wide variety of targets. These drugs are most commonly administered via the oral route.
- The only high-impact upcoming event in the fibromyalgia space is topline Phase IIa trial results for ASP0819. The overall likelihood of approval of a Phase I pain asset is 7.2%, and the average probability a drug advances from Phase III is 58.6%. Drugs, on average, take 9.3 years from Phase I to approval, compared to 9.8 years in the overall neurology space.
- The distribution of clinical trials across Phase I–IV indicates that the majority of trials for fibromyalgia have been in the late phases of development, with 68% of trials in Phase III–IV, and 32% in Phase I–II.
- The US has a substantial lead in the number of fibromyalgia clinical trials globally. Germany, Spain, and the UK lead the major EU markets, while India has the top spot in Asia.
- Clinical trial activity in the fibromyalgia space is dominated by completed trials. Pfizer has the highest number of completed clinical trials for fibromyalgia, with 23 trials.
- Pfizer leads industry sponsors with the highest overall number of clinical trials for fibromyalgia, followed by Allergan.
CONTENTS
5 OVERVIEW
6 KEY TAKEAWAYS
7 DISEASE BACKGROUND
7 Disease definition
7 Symptoms
7 Patient subtypes
8 Risk factors
8 Diagnosis
10 TREATMENT
10 Pharmacologic therapies
12 EPIDEMIOLOGY
12 Fibromyalgia prevalence
13 MARKETED DRUGS
15 PIPELINE DRUGS
21 RECENT EVENTS AND ANALYST OPINION
21 Multiple Drugs for Fibromyalgia (June 25, 2019)
21 NYX-2925 for Fibromyalgia (June 10, 2019)
23 NYX-2925 for Fibromyalgia (December 3, 2018)
26 KEY UPCOMING EVENTS
27 PROBABILITY OF SUCCESS
28 PARENT PATENTS
29 REVENUE OPPORTUNITY
30 CLINICAL TRIAL LANDSCAPE
31 Sponsors by status
32 Sponsors by phase
34 BIBLIOGRAPHY
34 Prescription information
36 APPENDIX
LIST OF FIGURES
15 Figure 1: Overview of pipeline drugs for fibromyalgia in the US
16 Figure 2: Pipeline drugs for fibromyalgia, by company
16 Figure 3: Pipeline drugs for fibromyalgia, by drug type
16 Figure 4: Pipeline drugs for fibromyalgia, by classification
23 Figure 5: NYX-2925 for Fibromyalgia (June 10, 2019): Phase II – Pilot Study
25 Figure 6: NYX-2925 for Fibromyalgia (December 3, 2018): Phase II – Pilot Study
26 Figure 7: Key upcoming events in fibromyalgia
27 Figure 8: Probability of success in the fibromyalgia pipeline
28 Figure 9: Parent patents in fibromyalgia
30 Figure 10: Clinical trials in fibromyalgia
30 Figure 11: Top 10 drugs for clinical trials in fibromyalgia
31 Figure 12: Top 10 companies for clinical trials in fibromyalgia
31 Figure 13: Trial locations in fibromyalgia
32 Figure 14: Fibromyalgia trials status
33 Figure 15: Fibromyalgia trials sponsors, by phase
LIST OF TABLES
14 Table 1: Marketed drugs for fibromyalgia
18 Table 2: Pipeline drugs for fibromyalgia in the US
21 Table 3: Multiple Drugs for Fibromyalgia (June 25, 2019)
22 Table 4: NYX-2925 for Fibromyalgia (June 10, 2019)
24 Table 5: NYX-2925 for Fibromyalgia (December 3, 2018)
29 Table 6: Historical global sales, by drug ($m), 2014–18
29 Table 7: Forecasted global sales, by drug ($m), 2019–23
© Informa UK Ltd. This document is a licensed product and is not to be reproduced or redistributed
Do you have a subscription to Datamonitor Healthcare, Biomedtracker or Meddevicetracker? You may already have access to these reports, contact your account manager or email pharma@informabi.com for further help or assistance.
Sign up to the